Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luigi Barbato

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Journal of the Neurological Sciences|May 22, 2016
Impact of a switch to fingolimod on depressive symptoms in patients with relapsing multiple sclerosis: An analysis from the EPOC (Evaluate Patient OutComes) trialSamuel F Hunter, Mark Agius, Deborah M Miller, et al.
BMC Neurology|November 27, 2014
Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trialJonathan Calkwood, Bruce Cree, Heidi Crayton, et al.
Journal of Periodontology|August 26, 2024
Diagnostic reproducibility of the 2018 Classification of Gingival Recessions: Comparing photographic and in-person diagnosesRiccardo Di Gianfilippo, GiovanPaolo Pini Prato, Debora Franceschi, et al.
Multiple Sclerosis and Related Disorders|August 13, 2015
Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosisEdward Fox, Keith Edwards, Gordon Burch, et al.
Multiple Sclerosis and Related Disorders|August 13, 2015
First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosisBruce Hughes, Mark Cascione, Mark S Freedman, et al.
Oral Diseases|November 27, 2023
The impact of COVID-19 on Italian dentists: A cross-sectional survey on 2443 participantsLuigi Barbato, Nicola Discepoli, Marco Clementini, et al.
Oral Diseases|October 30, 2020
Aerosol transmission for SARS-CoV-2 in the dental practice. A review by SIdP Covid-19 task-forceMarco Clementini, Mario Raspini, Luigi Barbato, et al.
Oral Diseases|September 18, 2020
Surface disinfection and protective masks for SARS-CoV-2 and other respiratory viruses: A review by SIdP COVID-19 task forceLuigi Barbato, Francesco Bernardelli, Giovanni Braga, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Journal of the Neurological Sciences|May 22, 2016
Impact of a switch to fingolimod on depressive symptoms in patients with relapsing multiple sclerosis: An analysis from the EPOC (Evaluate Patient OutComes) trialSamuel F Hunter, Mark Agius, Deborah M Miller, et al.
BMC Neurology|November 27, 2014
Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trialJonathan Calkwood, Bruce Cree, Heidi Crayton, et al.
Journal of Periodontology|August 26, 2024
Diagnostic reproducibility of the 2018 Classification of Gingival Recessions: Comparing photographic and in-person diagnosesRiccardo Di Gianfilippo, GiovanPaolo Pini Prato, Debora Franceschi, et al.
Multiple Sclerosis and Related Disorders|August 13, 2015
Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosisEdward Fox, Keith Edwards, Gordon Burch, et al.
Multiple Sclerosis and Related Disorders|August 13, 2015
First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosisBruce Hughes, Mark Cascione, Mark S Freedman, et al.
Oral Diseases|November 27, 2023
The impact of COVID-19 on Italian dentists: A cross-sectional survey on 2443 participantsLuigi Barbato, Nicola Discepoli, Marco Clementini, et al.
Oral Diseases|October 30, 2020
Aerosol transmission for SARS-CoV-2 in the dental practice. A review by SIdP Covid-19 task-forceMarco Clementini, Mario Raspini, Luigi Barbato, et al.
Oral Diseases|September 18, 2020
Surface disinfection and protective masks for SARS-CoV-2 and other respiratory viruses: A review by SIdP COVID-19 task forceLuigi Barbato, Francesco Bernardelli, Giovanni Braga, et al.
Pageof 4